DrugPatentWatch Database Preview

Mission Pharma Company Profile

« Back to Dashboard

What is the competitive landscape for MISSION PHARMA, and what generic alternatives to MISSION PHARMA drugs are available?

MISSION PHARMA has fifteen approved drugs.

There are two US patents protecting MISSION PHARMA drugs.

Summary for Mission Pharma

US Patents:	2
Tradenames:	14
Ingredients:	12
NDAs:	15

Drugs and US Patents for Mission Pharma

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mission Pharma	EQUIPIN	homatropine methylbromide	TABLET, CHEWABLE;ORAL	086310-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Mission Pharmacal Co	POTASSIUM IODIDE	potassium iodide	SOLUTION;ORAL	206211-001	Mar 24, 2016		OTC	No	No
Mission Pharma	LITHOSTAT	acetohydroxamic acid	TABLET;ORAL	018749-001	May 31, 1983		RX	Yes	Yes
Mission Pharma	CALCIBIND	cellulose sodium phosphate	POWDER;ORAL	018757-002	Dec 28, 1982		DISCN	No	No
Mission Pharma	HOMAPIN-5	homatropine methylbromide	TABLET;ORAL	086309-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Mission Pharma	BINOSTO	alendronate sodium	TABLET, EFFERVESCENT;ORAL	202344-001	Mar 12, 2012		RX	Yes	Yes	7,964,212		Y	Y
Mission Pharma	UROCIT-K	potassium citrate	TABLET, EXTENDED RELEASE;ORAL	019071-003	Dec 30, 2009	AB	RX	Yes	Yes

International Patents for Mission Pharma Drugs

Country	Document Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004035004
Austria	541575
World Intellectual Property Organization (WIPO)	03075884
Denmark	1490024
Australia	2003284275
European Patent Office	1490024
Spain	2448501

Supplementary Protection Certificates for Mission Pharma Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB10/012	United Kingdom		PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C/GB95/010	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
C0055	France		PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
C0026	France		PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
C/GB12/028	United Kingdom		PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
C/GB98/031	United Kingdom		PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Mission Pharma
• Mission Pharmacal Co